Switch to:
More From Other Websites
USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative... Mar 21 2017
Achillion Pharmaceuticals, Inc. :ACHN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
These 5 Stocks Under $10 Could Explode Up Soon Mar 02 2017
ACHILLION PHARMACEUTICALS INC Financials Mar 01 2017
Achillion Pharmaceuticals to Support a Natural History Study of C3 Glomerulopathy, a Rare Renal... Feb 28 2017
Achillion (ACHN) Reports Narrower-Than-Expected Q4 Loss Feb 27 2017
Biotech Movers: Cempra Flys High On Phase Three Results Feb 24 2017
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US :... Feb 24 2017
Achillion reports 4Q loss Feb 23 2017
Achillion reports 4Q loss Feb 23 2017
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 23 2017
ACHILLION PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Feb 23 2017
Achillion Reports 2016 Fourth Quarter and Year-End Financial Results Feb 23 2017
Biotech's Rally Continues to Build in 2017: Today's Reports on Achillion Pharmaceuticals and... Feb 22 2017
Achillion to Present at the Leerink Partners 6th Annual Global Healthcare Conference Feb 13 2017
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US :... Feb 03 2017
Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen Feb 02 2017
Coverage initiated on Achillion Pharma by Ladenburg Thalmann Feb 02 2017
Blog Coverage FDA Approved Orphan Drug Designation for TG Therapeutics' Combination of TG-1101 and... Jan 25 2017
Achillion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACHN) : January 11, 2017 Jan 11 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK